- Xenical is indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. Xenical is also indicated to reduce the risk for weight regain after prior weight loss. Xenical is indicated for obese patients with an initial body mass index (BMI) 3 30 kg/m2 or 3 27 kg/m2 in the presence of other risk factors (e.g., hypertension, diabetes, dyslipidemia).
- Phentermine (Adipex-P, Suprenza) is indicated as a short term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index (BMI) 3 30 kg/m2 or 3 27 kg/m2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, dyslipidemia).
- Desoxyn is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children over 6 years of age with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.
- Desoxyn is indicated as a short-term (i.e., a few weeks) adjunct in a regimen of weight reduction based on caloric restriction, for patients in whom obesity is refractory to alternative therapy, e.g., repeated diets, group programs, and other drugs.
- Qsymia is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia.
- Belviq is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of:
- ≥30 kg/m2
OR
- ≥27 kg/m2 in the presence of at least one weight-related comorbid condition (e.g. hypertension, dyslipidemia, type 2 diabetes)
- Contrave is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).
- Alli is an over-the-counter product indicated for weight loss in overweight adults, when used along with a reduced-calorie and low-fat diet.
- Tenuate and Tenuate Dospan are indicated as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction for the management of exogenous obesity patients with an initial BMI of > 30 kg/m2 and who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone.
- Benzphetamine (Didrex, Regimex) is indicated as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction for the management of exogenous obesity patients with an initial BMI of > 30 kg/m2 and who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone.
- Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).